Home › All Companies › ATNM › Current Report

Actinium Pharmaceuticals, Inc. (ATNM) — Current Report

AI-Powered SEC Filing Analysis

← All ATNM filings
Latest Current Report Filed: 2026-02-13

Key Insights

  • Actinium Pharmaceuticals announced the resignation of their Chief Financial Officer, Steve O'Loughlin, to pursue other opportunities, effective February 27, 2026.
  • The Board of Directors has appointed the current Chairman and CEO, Sandesh Seth, to serve as the principal financial officer of the company, effective February 27, 2026.
  • Sandesh Seth has over 25 years of experience in investment banking, equity research, and the pharmaceutical industry, which may help provide stability during the CFO transition.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Actinium Pharmaceuticals, Inc.

Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.